SCHEMBL5567583

SCHEMBL5567583

CCCCCCCC(=O)N(C)Cc1cccc(-c2ccc(C[C@H](OCC)C(=O)O)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 11/20 0.47
PPARG P37231 7/20 0.47
PPARA Q07869 7/20 0.47
PPARD Q03181 5/20 0.45
LTB4R2 Q9NPC1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6184829 1.00 AOC3 (0.47) AOC3PPARGPPARAPPARDLTB4R2
SCHEMBL6186234 0.90 PPARG (0.55) AOC3PPARGPPARA
SCHEMBL5383129 0.90 PPARG (0.48) AOC3PPARGPPARAPPARDLTB4R2
SCHEMBL5383133 0.90 PPARG (0.48) AOC3PPARGPPARAPPARDLTB4R2
SCHEMBL1749436 0.88 PPARG (0.48) AOC3PPARGPPARAPPARD
SCHEMBL1750740 0.87 PPARG (0.48) AOC3PPARGPPARAPPARD
SCHEMBL3944607 0.86 AOC3 (0.42) AOC3
SCHEMBL6183287 0.84 AOC3 (0.47) AOC3
SCHEMBL6184310 0.84 AOC3 (0.47) AOC3
SCHEMBL3947110 0.84 AOC3 (0.51) AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070065471-A1 Cosmetic/dermatological applications of PPAR receptor activators GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-03-22 US claimed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP claimed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US claimed
US-20070065471-A1 Cosmetic/dermatological applications of PPAR receptor activators GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-03-22 US disclosed
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD AOC3 1747/4885PPARG 1/4885PPARA 2/4885
US-20070065471-A1 Cosmetic/dermatological applications of PPAR receptor activators PPARG, PPARA, PPARD AOC3 3323/4885PPARG 1/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.